secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2023-07-25T23:59:59+00:00
Accession:  0001193125-23-193424
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Aligos shareholders elect three Class III directors and ratify Ernst & Young as auditor at 2023 Annual Meeting
--------------------------------------------------------------------------------

- Jack B. Nielsen (20,201,692 For), Bridget Martell (24,022,757 For), and Carole Nuechterlein (21,653,372 For) elected as Class III directors with 9,713,860 broker non-votes.
- Ernst & Young ratified as independent auditor for FY2023: 34,670,204 For, 11,096 Against, 918 Abstain.
- As of record date May 23, 2023, 40,410,244 shares were outstanding and entitled to vote.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000119312523193424/0001193125-23-193424-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000119312523193424/d428056d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-193424

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer